Compared to the untransduced T-cell cohort, CD19.CAR T cell-treated mice have significantly increased the percentage of CD8 T cells and reduced CLL B cells in the spleens, suggesting that the model is suitable for developing strategies to improve the efficacy of CARs in CLL (Figure 1). This evidence concerns the gene CD8A and B-cell chronic lymphocytic leukemia.